Novo Nordisk, Aspect sign $2.6bn diabetes cell therapy deal

Novo Nordisk has put $75 million down on the table to partner Canadian biotech Aspect Biosystems’ cell-based therapies for diabetes and obesity.

NICE backs "artificial pancreas" tech for type 1 diabetics

More than 100,000 people in England and Wales with type 1 diabetes that they find hard to control with current therapy could soon be offered new technology via the NHS.

Abbott joins alliance to bring 'artificial pancreas' system ...

Abbott has joined forces with two other companies to bring an automated insulin delivery (AID) system to people with diabetes in Europe that will monitor blood glucose levels and deliver in

Artificial pancreas will be piloted in 1,000 diabetics, says...

NHS England will provide artificial pancreas devices to 1,000 type 1 diabetes patients as part of a pilot study of the technology, according to chief executive Sir Simon Stevens.

FDA approves Tandem’s connected insulin controller

Artificial pancreas outperforms current tech in type 1 diabe...

An “artificial pancreas” has proved to be more effective at controlling blood sugar than injections with insulin by patients or with a pump, in an international trial mainly funded by the U